brentuximab vedotin Injection

Brand(s)
Adcetris
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Seattle Genetics, Inc. (2015-11-17)
Oldest Current Product
2011-08-25
License(s)
BLA
RxNORM
INJECTION\BRENTUXIMAB VEDOTIN
SPL Active
INTRAVENOUS\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\BRENTUXIMAB VEDOTIN
SPL Moiety
INTRAVENOUS\INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION\BRENTUXIMAB VEDOTIN

product(s) by strength(s)

brentuximab vedotin 50 mg injection

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1511440050AdcetrisBLASeattle Genetics, Inc.2011-08-25BRENTUXIMAB VEDOTININTRAVENOUSINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION1253883904f8dd-1aef-3490-e48f-bd55f32ed67f

application(s)

#idtitleapprovedtradenamesfda division
1125388brentuximab vedotin Application2011-08-19AdcetrisCDER

spl(s)

#idtitlecategorytypelabelerlabeler actlast updateversionproduct(s)
13904f8dd-1aef-3490-e48f-bd55f32ed67f (view SPL)These highlights do not include all the information needed to use ADCETRIS safely and effectively. See full prescribing information for ADCETRIS. ADCETRIS (brentuximab vedotin) for injection, for intravenous use Initial U.S. approval: 2011prescriptionHuman PrescriptionSeattle Genetics, Inc.analysis, manufacture2015-11-1715511440050

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII